Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit
Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit
1×1 investor meetings will be available after the event upon request by contacting your Lytham representative at RVPH@LythamPartners.com.CUPERTINO, Calif., Jan. 07, 2025 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a webcasted presentation at the Lytham Partners 2025 Investor Healthcare Summit, taking place virtually on Monday, January 13, 2025.
加利福尼亞州庫比蒂諾，2025年1月7日——Reviva Pharmaceuticals Holdings, Inc.（納斯達克：RVPH）（「Reviva」或「公司」）是一家晚期藥品公司，開發旨在滿足中央神經系統（CNS）、炎症和心代謝疾病領域未滿足醫療需求的療法，今天宣佈，Reviva創始人、總裁兼首席執行官Laxminarayan Bhat博士將參加於2025年1月13日（星期一）在Lytham Partners 2025年投資者醫療峯會上進行的網絡會議。
Company Webcast
公司網絡直播
The webcasted presentation will take place at 12:30 p.m. ET on Monday, January 13, 2025. The webcast can be accessed by visiting the conference home page at or directly at . A replay of the presentation will also be available through same links.
網絡直播展示將於2025年1月13日（星期一）下午12:30（東部時間）進行。通過訪問會議主頁或直接訪問，可以訪問網絡直播。展示的重播也將通過相同鏈接提供。
1×1 investor meetings will be available after the event upon request by contacting your Lytham representative at RVPH@LythamPartners.com.
活動結束後，可以根據要求通過聯繫您的Lytham代表，安排1對1的投資者會議。 RVPH@LythamPartners.com.
About Reviva
關於 Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva's current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva's pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Reviva是一家晚期生物製藥公司，致力於發現、開發並尋求商業化針對未滿足醫療需求以及對社會、患者和其家庭造成負擔的疾病的下一代治療藥物。Reviva目前的研發管線專注於中樞神經系統（CNS）、炎症和心代謝疾病。Reviva的管線目前包括兩個藥物候選者，分別爲brilaroxazine（RP5063）和RP1208。這兩個藥物都是在公司內部發現的新化學實體。Reviva已在美國、歐洲及其他幾個國家獲得了brilaroxazine和RP1208的物質組成專利。
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
公司聯繫方式：
Reviva Pharmaceuticals Holdings，Inc.
拉克希米納拉揚·巴特，博士
Investor Relations Contact:
LifeSci Advisors, LLC
Bruce Mackle
bmackle@lifesciadvisors.com
投資者關係聯繫：
生命科學顧問公司
布魯斯·麥克爾
bmackle@lifesciadvisors.com
譯文內容由第三人軟體翻譯。
